In terms of Regulation 29 (1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Supriya Lifescience has informed that a meeting of the Board of Directors of the Company will be held on Monday, October 28, 2024, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2024. With reference to its letter dated September 26, 2024 and in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and the Company’s Code of Conduct for Prevention of Insider Trading, the 'Trading Window’ for dealing in the securities of the Company shall continue to remain closed till 48 hours after announcement of Unaudited Financial Results for the quarter and half year ended September 30, 2024.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.00 |
| Dr. Reddys Lab | 1235.20 |
| Cipla | 1211.30 |
| Zydus Lifesciences | 923.10 |
| Lupin | 2312.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: